Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity. Obesity is a complex disease that occurs when an individual’s weight is higher than what is considered healthy for his/her height. According to the CDC, people with a body mass index (BMI) between 25 and 29.9 are considered overweight, and people with …